Gregory V. Kryukov

This study identifies Regnase-1 and SOCS1 dual-inactivation as a strategy to enhance anti-tumor functionality of CD8+ T cells by rewiring their differentiation and effector state.

DrugMap quantitatively analyzes cysteine ligandability across 416 cancer cell lines, revealing redox state, conformational changes, and mutations as drivers of variability, and identifies covalent inhibitors targeting NFκB1 and SOX10.

This study uses CRISPR/Cas9 screens to identify SOCS1 as a target for enhancing T cell therapy, leading to the development of an engineered TIL therapy with improved anti-tumor function.